usa

usa

31. Efforts to make pharmaceutical industry “profits” the scapegoat for rising health costs ignore economic reality

32. Commerce Department study of Pharmaceutical Price Controls in OECD Countries finds that price controls decrease available funding for R&D

33. H.H.S. report on drug importation concludes that there are significant risks associated with importing drugs for personal use

34. Advertising of prescription drugs can have a major impact on under-treated and under-diagnosed conditions and can help improve health outcomes

35. Higher costs for physician and institutional services account for most of the differences in health spending between Canada and the United States

36. State-sanctioned drug importation websites demonstrate problems regulating quality, safety and patient privacy standards of foreign pharmacies

37. Patients throughout the world rely on American health related R&D to find tomorrow’s treatments and cures

38. Minnesota results demonstrate the effectiveness of disease management programs in improving outcomes for chronic conditions

39. Substantial differences in health costs between the United States and Canada and other developed countries reflect similar differences in liability costs

40. Excessive medical liability litigation contributes to higher health costs by prompting American physicians to unnecessarily prescribe drugs and other treatments

<< Start < Prev 1 2 3 4 5 6 Next > End >>

Powered by Tags for Joomla

Top Topics

Latest News

Popular Articles

Social Media

Login

Who's Online

We have 136 guests online

Latest Events

No events